3i-1262 is a small molecule GATA4-acting compound that inhibit the GATA4-NKX2-5 interaction, enhances cardiomyocyte identity and maturity.
3i-1262 is a more potent inhibitor (64% vs. 38%, synergy of GATA4 and NKX2-5 inhibition) than 3i-1000.
3i-1262 (30 uM) significantly attenuates ET-1-induced BNP activation in neonatal rat ventricular myocytes (NRVMs), significantly inhibits stretch-induced NPPB gene expression.
3i-1262 induces cardiomyocyte metabolic processes and attenuates cell cycle processes in hiPSC-CMs.
3i-1262 induces maturation-related gene expression in hiPSC-CMs.
3i-1262 reorganises the cardiac TF network and converts hypertrophic signalling towards enhanced cardiomyocyte specification and maturity.
